Santen Pharmaceutical Co (SNPHY) Price & Analysis

Compare

6 Followers

SNPHY Stock Chart & Stats

$9.99

-$0.45(-4.61%)

At close: Jan 08 4:00 PM EST

$9.99

-$0.45(-4.61%)

Day’s Range― - ―

52-Week Range$8.88 - $12.05

Previous CloseN/A

Volume180.00

Average Volume (3M)1.01K

Market Cap

$3.45B

Enterprise Value$3.54B

Total Cash (Recent Filing)$84.58B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)16.5

Beta0.10

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Sep 30, 2025

Dividend Yield2.12%

Share Statistics

EPS (TTM)0.12

Shares Outstanding342,068,540

10 Day Avg. Volume2,904

30 Day Avg. Volume1,010

Financial Highlights & Ratios

PEG Ratio0.32

Price to Book (P/B)1.73

Price to Sales (P/S)1.65

P/FCF Ratio9.12

Enterprise Value/Market Cap1.03

Enterprise Value/Revenue0.01

Enterprise Value/Gross Profit0.02

Enterprise Value/Ebitda0.06

Forecast

1Y Price Target

$11.50

Price Target Upside15.12% Upside

Rating ConsensusHold

Number of Analyst Covering1

SNPHY FAQ

What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?

Santen Pharmaceutical Co Ltd lowest stock price was $8.88 and its highest was $12.05 in the past 12 months.

What is Santen Pharmaceutical Co Ltd’s market cap?

Santen Pharmaceutical Co Ltd’s market cap is $3.45B.

When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?

Santen Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.

How were Santen Pharmaceutical Co Ltd’s earnings last quarter?

Santen Pharmaceutical Co Ltd released its earnings results on Aug 07, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of N/A by $0.12.

Is Santen Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Santen Pharmaceutical Co Ltd pay dividends?

Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.128 which represents an annual dividend yield of 2.12%. See more information on Santen Pharmaceutical Co Ltd dividends here

What is Santen Pharmaceutical Co Ltd’s EPS estimate?

Santen Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Santen Pharmaceutical Co Ltd have?

Santen Pharmaceutical Co Ltd has 342,068,540 shares outstanding.

What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?

Santen Pharmaceutical Co Ltd reported an EPS of $0.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.177%.

Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in SNPHY

Santen Pharmaceutical Co Stock Smart Score

Neutral

Fundamentals

Return on Equity

10.89%

Trailing 12-Months

Asset Growth

4.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co (SNPHY) Earnings & Revenues

Historic Earnings Reports

SNPHY Stock 12 Month Forecast

Average Price Target

$11.50

▲(15.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","11":"$11","14":"$14","9.5":"$9.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,9.5,11,12.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2019","6":"Nov<br/>2019","9":"Jun<br/>2020","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.18,11.204615384615384,11.22923076923077,11.253846153846153,11.278461538461539,11.303076923076922,11.327692307692308,11.352307692307692,11.376923076923077,11.401538461538461,11.426153846153847,11.45076923076923,11.475384615384616,{"y":11.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.18,11.204615384615384,11.22923076923077,11.253846153846153,11.278461538461539,11.303076923076922,11.327692307692308,11.352307692307692,11.376923076923077,11.401538461538461,11.426153846153847,11.45076923076923,11.475384615384616,{"y":11.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.18,11.204615384615384,11.22923076923077,11.253846153846153,11.278461538461539,11.303076923076922,11.327692307692308,11.352307692307692,11.376923076923077,11.401538461538461,11.426153846153847,11.45076923076923,11.475384615384616,{"y":11.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.69,"date":1556668800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1559347200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1561939200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1564617600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1567296000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1569888000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1572566400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1575158400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.69,"date":1575158400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.69,"date":1590969600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >